FMP
Janux Therapeutics, Inc.
JANX
NASDAQ
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
47.1 USD
-1.11 (-2.36%)
About
ceo
Dr. David Alan Campbell Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.januxrx.com
exchange
NASDAQ
Description
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many can...
CIK
0001817713
ISIN
US47103J1051
CUSIP
47103J105
Address
11099 North Torrey Pines Road
Phone
858 750 4700
Country
US
Employee
64
IPO Date
Jun 11, 2021
Summary
CIK
0001817713
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
47103J105
ISIN
US47103J1051
Country
US
Price
47.1
Beta
4.18
Volume Avg.
938.72k
Market Cap
2.43B
Shares
-
52-Week
5.65-58.694
DCF
-0.95
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-35.68
P/B
-
Website
https://www.januxrx.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest JANX News
It looks like there's no news available.
